Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
Conditions
Brief summary
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Interventions
DRUGIMGN529
Sponsors
ImmunoGen, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Relapsed or refractory NHL including tumor types: Follicular lymphoma (FL), marginal zone lymphoma (MZL)/mucosa-associated lymphoid tissue (MALT), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL). * Adequate organ function * ECOG ≤ 2 * Recovered or stabilized from prior treatments.
Exclusion criteria
* Allogeneic stem cell transplantation * Pregnant or lactating females * Known central nervous system, meningeal or epidural disease including brain metastases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of dose limiting toxicities | During study |
Countries
Switzerland, United States
Outcome results
None listed